HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

frovocimab

Anticholesteremic; PCSK9 neutralizing monoclonal antibody

Also Known As:

LY-3015014; LY3015014

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        frovocimab: 2
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        frovocimab: 2
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        frovocimab: 2

Experts

1.	Ge, Xiaoyue: 1 article (01/2021)
2.	Huang, Keke: 1 article (01/2021)
3.	Li, Juan: 1 article (01/2021)
4.	Wan, Jinjin: 1 article (01/2021)
5.	Xie, Shanshan: 1 article (01/2021)
6.	Yang, Huiyao: 1 article (01/2021)
7.	Yu, Xin: 1 article (01/2021)
8.	Zeng, Hao: 1 article (01/2021)
9.	Zhang, Weifang: 1 article (01/2021)
10.	Zhu, Tiantian: 1 article (01/2021)

Related Diseases

1.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/01/2021 - "A computer was used to search the electronic Cochrane Library, PubMed/MEDLINE, and Embase databases for clinical trials using the following search terms: "AMG 145", "evolocumab", "SAR236553/REGN727", "alirocumab", "RG7652", "LY3015014", "RN316/bococizumab", "PCSK9", and "familial hypercholesterolemia" up to November 2020. "
2.	Hypercholesterolemia 01/01/2017 - "LY3015014 PK profile was consistent across all the studies and between healthy subjects and hypercholesterolemia patients. " 01/01/2017 - "Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients." 01/01/2017 - "LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9 and reduce low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia that is poorly controlled by maximally tolerated statin therapy. "

Related Drugs and Biologics

1.	evolocumab
2.	alirocumab
3.	RG7652
4.	bococizumab
5.	Subtilisin
6.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
7.	Proteins (Proteins, Gene)
8.	LDL Cholesterol
9.	Immunoglobulins (Immunoglobulin)
10.	Immunoglobulin G (IgG)

Related Therapies and Procedures

1.	Therapeutics